Investigational drug · Phase 3
KL-A167
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Recurrent or Metastatic.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
12
Any phase or sponsor naming "KL-A167"
First trial start
2022
May 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KL-A167", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic
- Small Cell Lung Cancer
- Triple-negative Breast Cancer and HR+/HER2- BC
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KL-A167" as an intervention, largest first.
- KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaPivotal-lookingActive, not recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05294172 · 295 participants · Start Jun 7, 2022 · Primary completion Dec 2027
Drug: KL-A167; Gemcitabine and 2 more · For: Nasopharyngeal Carcinoma; Recurrent or Metastatic
Sites: Beijing, China
- SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerPivotal-lookingCompleted
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05445908 · 184 participants · Start Aug 17, 2022 · Primary completion Jul 31, 2026
Drug: SKB264; KL-A167 · For: Triple-negative Breast Cancer and HR+/HER2- BC
Sites: Changsha, China; Nanjing, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT03848286 · 153 participants · Start Mar 6, 2019 · Primary completion Jul 13, 2021
Drug: KL-A167 Injection · For: Nasopharyngeal Carcinoma; Recurrent or Metastatic
Sites: Beijing, China
- SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05351788 · 110 participants (planned) · Start May 20, 2022 · Primary completion Aug 2026
Drug: SKB264; KL-A167 and 2 more · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China · 2 sites in all
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT03580564 · 109 participants · Start Aug 1, 2018 · Primary completion Aug 22, 2020
Drug: KL-A167 · For: Classical Hodgkin Lymphoma
Sites: Beijing, China
- SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological MalignanciesNot yet recruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT07738757 · 80 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2028
Drug: Sacituzumab Tirumotecan (Sac-TMT); Tagitanlimab · For: Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
Sites: Jinan, China; Beijing, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07296809 · 80 participants (planned) · Start Jan 30, 2026 · Primary completion Dec 31, 2028
Drug: SKB500 Powder for Injection; KL-A167 Injection and 2 more · For: Small Cell Lung Cancer
Sites: Guangzhou, China
Sun Yat-sen UniversityAcademic, hospital or other
NCT07701681 · 75 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 1, 2028
Drug: Sacituzumab Tirumotecan + Tagitanlimab · For: ESCC; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 2 more
Sites: Guangzhou, China
- SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNot yet recruiting
West China HospitalAcademic, hospital or other
NCT07109284 · 55 participants (planned) · Start Sep 2025 · Primary completion Jan 2028
Drug: Sacituzumab tirumotecan; Tagitanlimab · For: ER+HER2- Breast Cancer
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT07371208 · 40 participants (planned) · Start Dec 24, 2025 · Primary completion Aug 2028
Drug: SKB264 · For: Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Trajectories of Plasma Epstein-Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD-L1 Inhibitors: A Post-Hoc Analysis of a Multicenter, Phase II Study.
Pan Z, Pei Y, Diao J, et al. · Head Neck 2026
- Baseline Nutritional Indices as Prognostic Indicators in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with the PD-L1 Inhibitor KL-A167: A Secondary Analysis of the KL-A167 Trial.
Li H, Liu Z, Li J, et al. · Cancer Manag Res 2026
- Association of basal thyroid function with clinical outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-L1 inhibitor KL-A167: a multicenter post hoc analysis.
Chen K, Fan H, Xu S, et al. · Endocr Connect 2026
- First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.
Hong S, Wang Q, Cheng Y, et al. · Nat Med 2025
- Correction: Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Li Y, Min Y, Wei Z, et al. · Cancer Immunol Immunother 2025
- Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Li Y, Min Y, Wei Z, et al. · Cancer Immunol Immunother 2025
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.